Effects of Taurine Supplementation on Repetitive Sprint Performance and Exhaustion Time in College Students Under High-Temperature and High-Humidity Conditions

NCT06824571 | Completed

• 1 other identifier: No. 2021A43
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to evaluate the effects of acute pre-exercise taurine supplementation at different doses on the performance of college students during exhaustive exercise and subsequent repetitive sprint (RS) activities in a high-temperature, high-humidity environment. Sixteen college students (8 male, 8 female) will participate in a single-blind, randomized, crossover-controlled trial. Participants will be divided into four groups: high-dose taurine (6g), medium-dose taurine (4g), low-dose taurine (1g), and placebo. Key performance metrics such as peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump height, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE) will be measured. The objective of this study is to assess how taurine supplementation influences exercise performance under these challenging environmental conditions. This study will help to better understand taurine's potential effects on exercise performance and contribute to nutritional strategies for athletes exposed to extreme conditions.

Conditions

Exercise Performance in Extreme Environments

Outcome Measures

Primary Outcomes (5)

• Change from Baseline in Peak Power (Watts)

  Description: Maximum power output during each of the 6 sprints, measured using a cycle ergometer. Method of Assessment: Power output will be recorded for each sprint, and the peak value will be identified.

  Measured at the end of each sprint on Day 1 and Day 7.

• Change from Baseline in Mean Power (Watts)

  Description: Average power output across all 6 sprints, reflecting sustained anaerobic performance. Method of Assessment: Power output will be averaged across all sprints.

  Measured after all 6 sprints on Day 1 and Day 7.

• Change from Baseline in Fatigue Index (%/s)

  Description: Rate of decline in power output across the sprints, representing fatigue resistance. Method of Assessment: The decline in power output will be calculated as the difference between the first and last sprint, divided by the time interval.

  Measured across all 6 sprints on Day 1 and Day 7.

• Change from Baseline in Exhaustion Time (seconds or minutes)

  Description: The duration participants can sustain exercise before reaching volitional exhaustion. Method of Assessment: Time will be recorded from the start of exercise until the participant reaches exhaustion.

  Measured at the point of exhaustion during exhaustive exercise on Day 1 and Day 7.

• Change from Baseline in Blood Lactate Levels (mmol/L)

  Description: Blood lactate levels will be measured to evaluate metabolic stress and recovery during exercise. Method of Assessment: Blood samples will be collected at designated time points during recovery to assess lactate accumulation and clearance.

  Measured at baseline (pre-exercise), immediately after exercise, and at specific recovery intervals on Day 1 and Day 7.

Secondary Outcomes (1)

• Change from Baseline in Ratings of Perceived Exertion (RPE)

  Measured continuously during exhaustive exercise and repetitive sprint activity on Day 1 and Day 7.

Study Arms (4)

High-Dose Taurine Group (6g)

EXPERIMENTAL

Participants in this arm will receive taurine supplementation at a high dose of 6g, dissolved in water, administered 30 minutes prior to exercise. High-Dose Taurine Supplementation (6g)

Dietary Supplement: High-Dose Taurine Supplementation (6g)

Medium-Dose Taurine Group (4g)

EXPERIMENTAL

Participants in this study arm will receive a medium dose of taurine supplementation (4g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to evaluate the effects of medium-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a moderate taurine dosage compared to the high-dose and low-dose groups.

Dietary Supplement: Medium-Dose Taurine Supplementation (4g)

Low-Dose Taurine Group (1g)

EXPERIMENTAL

Participants in this study arm will receive a low dose of taurine supplementation (1g) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This intervention aims to assess the effects of low-dose taurine on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure multiple parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of a smaller taurine dosage compared to the medium-dose and high-dose groups.

Dietary Supplement: Low-Dose Taurine Supplementation (1g)

Placebo Group

PLACEBO COMPARATOR

Participants in this study arm will receive a placebo (inactive substance) in powder form, dissolved in water, administered once 30 minutes prior to exercise. This group serves as the control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions. The study will measure key parameters, including peak power (PP), mean power (MP), fatigue index (FI), exhaustion time (ET), reverse vertical jump values, heart rate (HR), blood lactate (BLA), and ratings of perceived exertion (RPE). This arm is distinguished by the administration of an inactive placebo, which contains no taurine, to compare against the taurine intervention arms.

Dietary Supplement: Placebo (0g Taurine)

Interventions

High-Dose Taurine Supplementation (6g) DIETARY_SUPPLEMENT

Participants will receive taurine supplementation at a high dose of 6g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of high-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.

High-Dose Taurine Group (6g)

Medium-Dose Taurine Supplementation (4g) DIETARY_SUPPLEMENT

Participants will receive taurine supplementation at a medium dose of 4g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of medium-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.

Medium-Dose Taurine Group (4g)

Low-Dose Taurine Supplementation (1g) DIETARY_SUPPLEMENT

Participants will receive taurine supplementation at a low dose of 1g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of low-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.

Low-Dose Taurine Group (1g)

Placebo (0g Taurine) DIETARY_SUPPLEMENT

Participants will receive a placebo, consisting of an inactive substance (0g taurine). The placebo will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention serves as a control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.

Placebo Group

Eligibility Criteria

• Age: 20 Days - 26 Days
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• School students
• Aged between 18 and 28 years
• No exercise-related risk, as indicated by a "no" response to all questions in the Physical Activity Readiness Questionnaire (PAR-Q)
• No taurine-based supplements consumed in the last month.

You may not qualify if:

• Individuals with a history of cardiovascular issues, respiratory problems, or any condition that may impair exercise performance
• Participants who did not provide a "no" response to all questions in the Physical Activity Readiness Questionnaire (PAR-Q)
• Participants who consumed taurine-based supplements in the month preceding the study.

Sponsors & Collaborators

• Xiaodong Cheng: lead

Study Sites (1)

Capital University of Physical Education and Sports

Beijing, Beijing Municipality, 100191, China

Location

Related Links

• Official website of the Capital University of Physical Education and Sports, where the study was conducted.

MeSH Terms

Interventions

Taurine

Intervention Hierarchy (Ancestors)

Alkanesulfonic Acids; Alkanes; Hydrocarbons, Acyclic; Hydrocarbons; Organic Chemicals; Sulfonic Acids; Sulfur Acids; Sulfur Compounds

Study Officials

• Xiaodong Cheng, PhD

  Xi'an Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: The study employed a single-blind design where participants were masked to the intervention assignments. This means that participants were unaware of whether they received high-dose taurine (6g), medium-dose taurine (4g), low-dose taurine (1g), or placebo. The care providers and investigators were aware of the intervention assignments to ensure proper administration and data collection.
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Xian Medical University

Model Details: This study utilized a single-blind, randomized, crossover-controlled design to evaluate the effects of taurine supplementation at varying doses (6g, 4g, 1g) and placebo on exercise performance under high-temperature and high-humidity conditions. Each participant received all four interventions (high-dose, medium-dose, low-dose, and placebo) in randomized order, with a washout period between treatments to minimize carryover effects. This design allows each participant to serve as their own control, enhancing the precision of the comparisons across conditions.

Study Record Dates

• First Submitted: January 22, 2025
• First Posted: February 13, 2025
• Study Start: December 1, 2024
• Primary Completion: January 1, 2025
• Study Completion: January 9, 2025
• Last Updated: February 13, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: SAP
• Time Frame: The IPD and supporting information will be made available starting from 6 months after the publication of the study results and will remain available for 5 years.
• Access Criteria: The IPD and supporting information will be available to qualified researchers upon request. Access will be granted after a data-sharing agreement is signed to ensure the data will be used responsibly and in accordance with ethical guidelines. Researchers can request access by contacting the Principal Investigator at chengxiaodong@xiyi.edu.cn.

Locations

CN (1)